A Single- and Multiple-ascending Dose Study to Investigate Safety, Tolerability and Pharmacokinetics of NNC0662-0419 in Participants Living With Overweight or Obesity
Latest Information Update: 09 Jan 2025
Price :
$35 *
At a glance
- Drugs NNC 06620419 (Primary)
- Indications Obesity
- Focus Adverse reactions
- Sponsors Novo A/S; Novo Nordisk
- 07 Jan 2025 Status changed from not yet recruiting to recruiting.
- 25 Dec 2024 New trial record